In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock ...

In severe cases, you might have a stooped posture. This is more common in a different but related disease called ankylosing spondylitis. Still, exercise is important. It relieves pain and ...

People with ankylosing spondylitis sometimes develop arthritis in their hips and shoulders early on. It also can make you feel fatigued or lose your appetite. You might run a mild fever.

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.

Medicare coverage of this drug depends on the type of plan. Enbrel (etanercept) is a biologic medication, which means it is made from a live organism. It is available only by prescription.

Natural treatments for ankylosing spondylitis (AS), a type of inflammatory arthritis, can help you to deal with pain and stiffness in the spine and other joints. Exercise, nutrition, and smoking ...

Adma Biologics (ADMA) closed at $21.31 in the latest trading session, marking a +0.38% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day.

In patients with psoriasis or ankylosing spondylitis, the use of interleukin (IL)-17A inhibitors, particularly secukinumab, was associated with an increased risk for inflammatory bowel disease ...

Background: Ankylosing spondylitis (AS) is a progressive inflammatory disease causing severe kyphosis, which complicates surgical management and increases complication risks. This study aims to ...

Paving the way for launch of Yesafili? in the United States Biocon Biologics (BBL), subsidiary of Biocon, announced today a settlement and license agreement with Regeneron that clears the way to ...

Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US by the second half of 2026. Approved by the USFDA as an ...

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US. Yesafili, a vascular ...